Letrozole 2.5mg Tablets | 100-Count | Letrozole | AI
🇺🇸 1-Region Domestic Shipping
QSC Letrozole (Letrozole (non-steroidal aromatase inhibitor)) — ≥99% HPLC purity, MS confirmed, Janoshik COA. Research use only.
$130.00
* The information on this page is a summary and is not intended to cover all available information about this medication. It does not cover all possible uses, directions, precautions, drug interactions or adverse effects and is not a substitute for the expertise and judgement of your healthcare professional.
{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “How are QSC research tablets supplied?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “QSC research tablets are supplied as pre-dosed oral tablets at the stated concentration. No reconstitution is required. Each tablet is compressed at uniform dose for consistent dosing in research applications.”}}, {“@type”: “Question”, “name”: “How should research tablets be stored?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Store at room temperature (15–25°C) in a cool, dry place away from moisture, heat, and direct sunlight. Keep in the original container. Properly stored tablets remain stable for 2–3 years.”}}, {“@type”: “Question”, “name”: “What purity are QSC research tablets and how is it verified?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “QSC research tablets contain active ingredient at ≥99% HPLC purity before tableting, with MS-confirmed identity on every batch. COA is published on the product page and independently verifiable at verify.janoshik.com.”}}]}
What is Letrozole?
Letrozole is a third-generation non-steroidal aromatase inhibitor (Type II — reversible competitive CYP19A1 inhibition). ~99% estrogen suppression — most potent AI. Research: estrogen-sensitive cancer, T:E2 ratio manipulation, aromatase kinetics, male hypogonadism from aromatase excess, and Type I vs Type II AI comparison. CAS 112809-51-5.
Research Applications
Aromatase Inhibition
Reversible CYP19A1 competitive inhibition — ~99% estrogen suppression
Hormone-Sensitive Cancer
ER+ breast cancer estrogen deprivation models
T:E2 Ratio Manipulation
Testosterone/estradiol ratio titration in male models
AI Class Comparison
Non-steroidal (reversible) vs steroidal/irreversible AI mechanisms
Male Hypogonadism
Aromatase excess syndrome — estrogen-driven gonadotropin suppression
Quick Specs
| Form | Tablet — 2.5mg per tablet, 100-tablet bottle |
| CAS Number | 112809-51-5 |
| Molecular Formula | C₁₇H₁₁N₅ |
| Molecular Weight | 285.3 g/mol |
| Compound Type | SERM / Aromatase Inhibitor |
| Purity | ≥99% by HPLC — every batch |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house synthesis — Qingdao, China |
| Storage | Room temperature sealed | cool, dry storage |
| Shelf Life | 24 months unopened |
Certificate of Analysis (COA)
Frequently Asked Questions
Frequently asked questions
A seemingly elegant design can quickly begin to bloat with unexpected content or break under the weight of actual activity. Fake data can ensure a nice looking layout but it doesn’t reflect what a living, breathing application must endure. Real data does.
Websites in professional use templating systems. Commercial publishing platforms and content management systems ensure that you can show different text, different data using the same template. When it’s about controlling hundreds of articles, product pages for web shops.
A seemingly elegant design can quickly begin to bloat with unexpected content or break under the weight of actual activity. Fake data can ensure a nice looking layout but it doesn’t reflect what a living, breathing application must endure. Real data does.
Websites in professional use templating systems. Commercial publishing platforms and content management systems ensure that you can show different text, different data using the same template. When it’s about controlling hundreds of articles, product pages for web shops.
Reviews
Clear filtersThere are no reviews yet.